locke lord
  • Your search didn't return any results
  • Your search didn't return any results

Providence-Led Team Represents Biohaven Pharmaceutical and BioShin Limited in BioShin's $60 Million Series A Preferred Equity Financing

A Locke Lord team led by Douglas Gray, Kathrine Morin (Providence) and Ralph Loren (Boston), represented Biohaven Pharmaceutical Holding Company (NYSE: BHVN) and its affiliate BioShin Limited in a $60 million Series A Preferred equity financing of BioShin Limited, Biohaven's subsidiary that is scheduled to exploit Biohaven intellectual property in the Asia-Pacific territory. The financing was led by OrbiMed Asia, with participation from Cormorant Asset Management LLC, HBM Healthcare Investments Ltd, Surveyor Capital (a Citadel Company) and Suvretta Capital Management, LLC. BioShin will advance Biohaven's clinical portfolio in the Asia-Pacific region, addressing migraine, neurologic and neuropsychiatric diseases. Additional assistance with the transaction was provided by Lori Basilico, (Providence), Stephen Murphy (Washington) and Jaremi Chilton (San Francisco).
Posted on September 29, 2020

RELATED PROFESSIONALS
Douglas G. Gray
Partner
Kathrine Morin
Associate
Ralph A. Loren
Of Counsel
Lori A. Basilico
Partner
Stephen P. Murphy
Of Counsel
Jaremi Chilton
Partner
RELATED SERVICES
INDUSTRIES
Pharmaceutical
Disclaimer
Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.